Danaher’s Big Bet On Masimo: Hidden Synergies Or Integration Risk?

Recent reports indicate that Danaher is nearing a roughly $10 billion acquisition of Masimo, a U.S.-based medical technology company best known for its pulse oximetry platforms and noninvasive patient monitoring solutions. According to media coverage, the transaction could represent a significant premium to Masimo’s recent ~$7 billion market capitalization and would mark Danaher’s largest deal since its $21.4 billion acquisition of Cytiva in 2020. The timing is notable. Danaher has just delivered a solid 2025 finish, reporting $24.6 billion in revenue, 28%+ adjusted operating margins, and strong free cash flow conversion, while guiding for 3%–6% core growth in 2026. With bioprocessing momentum stabilizing and diagnostics improving globally, the potential Masimo acquisition appears to align with Danaher’s capital deployment strategy amid a “more constructive” M&A environment. The question now is not just whether the deal closes—but what strategic and financial synergies Danaher could realistically extract from such a transaction.